You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Tissue Collection for Studies of Lymph Cancer
Recruiting
  • Hodgkin Disease
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    U
    Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
    Recruiting
    • Adult T-cell Leukemia-Lymphoma
    • ATLL
    • Miami, Florida
      University of Miami
    2022-01-24
    Jan 24, 2022
    N
    Ruxolitinib for Adult T-Cell Leukemia - 2022
    Completed
    • T Cell Leukemia, Adult
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-01-26
    Jan 26, 2022
    N
    Biospecimen Procurement for Genitourinary Malignancies Branch Immunotherapy Protocols
    Recruiting
    • Multiple Myeloma
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-04-07
      Apr 7, 2022
      N
      Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
      Active, not recruiting
      Has Results
      • Adult T-Cell Leukemia (ATL)
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2022-01-13
      Jan 13, 2022
      A
      Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
      Not yet recruiting
      • Lymphoproliferation Induced by HTLV-1
      • +2 more
        • (no location specified)
        2022-02-09
        Feb 9, 2022
        N
        Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
        Not yet recruiting
        • Adult T-cell Leukemia/Lymphoma
        • +4 more
        • CC-486 (5-azacitidine)
        • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        2022-04-07
        Apr 7, 2022
        N
        Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
        Active, not recruiting
        Has Results
        • Adult T-Cell Lymphoma/Leukemia
        • +2 more
        • Recombinant human Interleukin-15 (rhIL-15)
        • Mogamulizumab
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        2021-11-17
        Nov 17, 2021
        U
        BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
        Recruiting
        • Lymphoma
        • +2 more
        • Brentuximab Vedotin
        • CHEP
        • Hollywood, Florida
        • +3 more
        2021-08-12
        Aug 12, 2021
        O
        A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
        Active, not recruiting
        • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
        • Yamagata, Japan
          Yamagata University Hospital
        2022-02-21
        Feb 21, 2022
        N
        Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) - 2021
        Completed
        • T-Cell Lymphoma Relapsed
        • +4 more
        • IL-15 plus alemtuzumab
        • Bethesda, Maryland
          National Institutes of Health Clinical Center, 9000 Rockville Pi
        2021-07-10
        Jul 10, 2021
        J
        Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
        Recruiting
        • Recurrent Adult T-Cell Leukemia/Lymphoma
        • +3 more
        • Columbus, Ohio
          Ohio State University Comprehensive Cancer Center
        2021-10-07
        Oct 7, 2021
        D
        A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
        Recruiting
        • T-cell Lymphoma
        • +5 more
        • Brentuximab vedotin
        • Ann Arbor, Michigan
        • +4 more
        2022-02-02
        Feb 2, 2022
        N
        Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
        Recruiting
        • Hairy Cell Leukemia (HCL)
        • +4 more
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          2022-04-07
          Apr 7, 2022
          W
          CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
          Active, not recruiting
          • Adult Lymphocyte Depletion Hodgkin Lymphoma
          • +16 more
          • 6,8-bis(benzylthio)octanoic acid
          • bendamustine hydrochloride
          • Winston-Salem, North Carolina
          • +1 more
          2021-10-28
          Oct 28, 2021
          D
          Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
          Active, not recruiting
          • Adult T-cell Leukemia/Lymphoma
          • Valemetostat Tosylate
          • Nagoya-shi, Aichi, Japan
          • +23 more
          2022-01-11
          Jan 11, 2022
          M
          Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
          Active, not recruiting
          Has Results
          • Adult Nasal Type Extranodal NK/T-cell Lymphoma
          • +20 more
          • Scottsdale, Arizona
          • +1 more
          2022-02-03
          Feb 3, 2022
          H
          Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) - 2019
          Completed
          • Adult T-Cell Lymphoma (ATL)
          • Fukuoka, Japan
          • +18 more
          2020-10-02
          Oct 2, 2020
          N
          Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
          Recruiting
          • Acute Adult T-Cell Leukemia/Lymphoma
          • +3 more
          • Atlanta, Georgia
          • +12 more
          2022-03-09
          Mar 9, 2022
          N
          Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma - 2015
          Completed
          Has Results
          • Adult Nasal Type Extranodal NK/T-cell Lymphoma
          • +35 more
          • Akt inhibitor MK2206
          • laboratory biomarker analysis
          • Houston, Texas
            M D Anderson Cancer Center
          2020-10-14
          Oct 14, 2020
          N
          Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia - 2013
          Terminated
          Has Results
          • Leukemia, Adult T-Cell
          • Denileukin diftitox (Ontak)
          • Bethesda, Maryland
            National Institutes of Health Clinical Center, 9000 Rockville Pi
          2019-11-08
          Nov 8, 2019
          M
          Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma - 2020
          Completed
          Has Results
          • Adult Nasal Type Extranodal NK/T-cell Lymphoma
          • +18 more
          • Scottsdale, Arizona
          • +1 more
          2020-09-28
          Sep 28, 2020
          M
          Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma - 2019
          Terminated
          Has Results
          • Blastic Plasmacytoid Dendritic Cell Neoplasm
          • +16 more
          • Laboratory Biomarker Analysis
          • Nivolumab
          • Rochester, Minnesota
            Mayo Clinic
          2020-04-20
          Apr 20, 2020
          C
          Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
          Active, not recruiting
          • Adult T-Cell Leukemia/Lymphoma
          • +10 more
          • Brentuximab Vedotin
          • +7 more
          • Duarte, California
          • +4 more
          2021-08-10
          Aug 10, 2021
          C
          A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma - 2013
          Completed
          • Adult T-cell Leukemia-Lymphoma
          • Peripheral T-cell Lymphoma
          • Fukuoka, Japan
          • +5 more
          2019-11-06
          Nov 6, 2019